JP2010506855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010506855A5 JP2010506855A5 JP2009532610A JP2009532610A JP2010506855A5 JP 2010506855 A5 JP2010506855 A5 JP 2010506855A5 JP 2009532610 A JP2009532610 A JP 2009532610A JP 2009532610 A JP2009532610 A JP 2009532610A JP 2010506855 A5 JP2010506855 A5 JP 2010506855A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- potassium phosphate
- phosphate buffer
- fenofibric acid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JWAZHODZSADEHB-UHFFFAOYSA-M 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate;2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.C1=CC(OC(C)(C)C([O-])=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 JWAZHODZSADEHB-UHFFFAOYSA-M 0.000 claims 15
- 229960003653 Choline Fenofibrate Drugs 0.000 claims 15
- 229960000701 fenofibric acid Drugs 0.000 claims 15
- 239000008057 potassium phosphate buffer Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 238000004090 dissolution Methods 0.000 claims 5
- 229960002297 Fenofibrate Drugs 0.000 claims 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N Fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000001509 sodium citrate Substances 0.000 claims 3
- 239000011778 trisodium citrate Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000002459 sustained Effects 0.000 claims 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical group COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82925506P | 2006-10-12 | 2006-10-12 | |
| PCT/US2007/081267 WO2008046052A1 (fr) | 2006-10-12 | 2007-10-12 | Formulations pharmaceutiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010506855A JP2010506855A (ja) | 2010-03-04 |
| JP2010506855A5 true JP2010506855A5 (fr) | 2010-09-30 |
Family
ID=38961056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009532610A Pending JP2010506855A (ja) | 2006-10-12 | 2007-10-12 | 医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2081563A1 (fr) |
| JP (1) | JP2010506855A (fr) |
| KR (1) | KR20090119959A (fr) |
| CN (1) | CN101677981A (fr) |
| AU (1) | AU2007307641A1 (fr) |
| CA (1) | CA2672686A1 (fr) |
| CO (1) | CO6160302A2 (fr) |
| EA (1) | EA200900531A1 (fr) |
| EC (1) | ECSP099251A (fr) |
| IL (1) | IL198160A0 (fr) |
| MX (1) | MX2009003815A (fr) |
| SG (1) | SG175570A1 (fr) |
| WO (1) | WO2008046052A1 (fr) |
| ZA (1) | ZA200902488B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102046153B (zh) * | 2008-05-30 | 2015-06-17 | Ucb医药有限公司 | 包含布立西坦的药物组合物 |
| CN102304103A (zh) * | 2011-06-03 | 2012-01-04 | 郑州泰基鸿诺药物科技有限公司 | 一种非诺贝特酸盐、制备方法、药物组合物及应用 |
| CN102659570B (zh) * | 2012-05-17 | 2014-05-28 | 安润医药科技（苏州）有限公司 | 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用 |
| FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
| CN107496397A (zh) * | 2016-06-14 | 2017-12-22 | 重庆安格龙翔医药科技有限公司 | 一种二甲双胍与非诺贝酸的复合物及其制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| EP1832285A1 (fr) * | 2002-12-17 | 2007-09-12 | Abbott GmbH & Co. KG | Formulation comprenant de l'acide fénofibrique ou l'un de ses sels physiologiquement acceptable |
| CN101480384A (zh) * | 2002-12-17 | 2009-07-15 | 阿伯特有限及两合公司 | 包含非诺贝酸、其生理可接受的盐或衍生物的制剂 |
| EP1559419A1 (fr) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir |
| US20060280790A1 (en) * | 2005-04-08 | 2006-12-14 | Ju Tzuchi R | Pharmaceutical formulations |
-
2007
- 2007-10-12 WO PCT/US2007/081267 patent/WO2008046052A1/fr active Application Filing
- 2007-10-12 JP JP2009532610A patent/JP2010506855A/ja active Pending
- 2007-10-12 SG SG2011070588A patent/SG175570A1/en unknown
- 2007-10-12 CA CA002672686A patent/CA2672686A1/fr not_active Abandoned
- 2007-10-12 CN CN200780045748A patent/CN101677981A/zh active Pending
- 2007-10-12 EP EP07844238A patent/EP2081563A1/fr not_active Withdrawn
- 2007-10-12 AU AU2007307641A patent/AU2007307641A1/en not_active Abandoned
- 2007-10-12 KR KR1020097007466A patent/KR20090119959A/ko not_active Application Discontinuation
- 2007-10-12 ZA ZA200902488A patent/ZA200902488B/xx unknown
- 2007-10-12 EA EA200900531A patent/EA200900531A1/ru unknown
- 2007-10-12 MX MX2009003815A patent/MX2009003815A/es not_active Application Discontinuation
-
2009
- 2009-04-13 EC EC2009009251A patent/ECSP099251A/es unknown
- 2009-04-13 CO CO09036680A patent/CO6160302A2/es unknown
- 2009-04-16 IL IL198160A patent/IL198160A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016006108A5 (fr) | ||
| JP2016525572A5 (fr) | ||
| JP2011526918A5 (fr) | ||
| JP2003502359A5 (fr) | ||
| JP2013501718A5 (fr) | ||
| JP2007119479A5 (fr) | ||
| JP2013501717A5 (fr) | ||
| NZ587897A (en) | Drug delivery systems comprising weakly basic drugs and organic acids | |
| JP2008503475A5 (fr) | ||
| JP2011079859A5 (fr) | ||
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| AU2014221630B2 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
| JP2013545762A5 (fr) | ||
| JP2008525335A (ja) | 経口投与できる固体の放出改変型医薬投与形 | |
| EP4205735A1 (fr) | Formulations de phénylacétate de l-ornithine | |
| NZ620887A (en) | A novel formulation of diclofenac | |
| JP2014508812A5 (fr) | ||
| JP2017532363A5 (fr) | ||
| JP2010506855A5 (fr) | ||
| JP2008522989A5 (fr) | ||
| JP2013531041A5 (fr) | ||
| CA2304135C (fr) | Formulation medicamenteuse a liberation controlee du principe actif | |
| CA3127926A1 (fr) | Methodes de traitement de la maladie de parkinson par l'administration d'apomorphine a une muqueuse orale | |
| US20150366807A1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| JP2005528430A5 (fr) |